CARSgen Therapeutics Holdings Ltd (HKG: 2171), a China-based specialist in chimeric antigen receptor (CAR)-T cell therapies, has announced the presentation of the latest data for its CAR-T therapies, CT053 (zevorcabtagene autoleucel; zevor-cel), CT071, and CT0590, at the 66th American Society of Hematology (ASH) annual meeting.
CT053 Phase II Study Subgroup Analysis
CT053, a B-cell maturation antigen (BCMA)-targeted CAR-T cell therapy, received approval in China in February this year for the treatment of relapsed/refractory multiple myeloma (RRMM) in patients who have progressed after at least three lines of treatment. In the Phase II study, 102 RRMM patients who received ≥ 3-line treatment were treated with CT053, achieving an objective response rate (ORR) of 92.2% and a stringent complete response (sCR) or complete response (CR) rate of 71.6%. Subgroup analysis indicates that baseline features have little impact on the clinical effectiveness of CT053, suggesting that RRMM patients with poor prognosis can also benefit from this therapy.
CT071 Clinical Study in RRMM
CT071, a GPRC5D-targeted CAR-T cell therapy, utilizes CARcelerate rapid production technology to reduce production time to about 30 hours, significantly shortening the time from single collection to reinfusion. This clinical trial enrolled RRMM patients who had failed at least three lines of treatment or developed resistance to at least one proteasome inhibitor and one immunomodulatory agent. Among the 17 patients receiving CT071 treatment, 11 (64.7%) developed cytokine release syndrome (CRS), all of which were grade 1 or grade 2. No immune effector cell-associated neurotoxicity syndrome (ICANS) was observed, and no dose limiting toxicity (DLT) occurred. The ORR is 94.1%, and the sCR rate is 52.9%.
First-in-Human Study for CT0590 in RRMM
CT0590, a triple knock-out, allogeneic CAR T-cell therapy targeting BCMA and NKG2A, deploys THANK uCAR technology to achieve dual targeting while reducing side effects such as graft-versus-host disease (GvHD) and host immune rejection. As of April 22, 2024, the Phase I study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CT0590 has enrolled 5 subjects. No grade ≥ 3 CRS, ICANS, or GvHD were observed. Three patients achieved remission, including two cases of sCR and one case of PR.- Flcube.com
